• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…
Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…
Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…
Topline data of the main cohort of AAVance clinical trial expected in Q3 2022Stabilization or…
Third patient treated in the global clinical trial with LYS-GM101 gene therapy program in GM1…
Cash and cash equivalents of €12.3 million[1] as of 31 December 2021 Paris, France —…
Lysogene remains focused on developing its pipeline led by LYS-SAF302, LYS-GM101, Fragile X and other…
Paris, France — 5 January 2022 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase 3…
The financing will enable Lysogene to accelerate the development of its gene therapy platformThe loan…
First step in the recent UK MHRA initiative to accelerate the development and access to…